Maternal care for anti-D [Rh] antibodies, second trimester (fetus 3)
ICD-10 O36.0123 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, second trimester (fetus 3).
O36.0123 refers to maternal care for a pregnant woman who has developed anti-D (Rh) antibodies during her second trimester, specifically concerning her third fetus. This condition arises when an Rh-negative mother is exposed to Rh-positive fetal blood, leading to the production of antibodies that can cross the placenta and potentially harm the fetus. The presence of these antibodies can result in complications such as hemolytic disease of the newborn, fetal growth restriction, and fetal distress. Monitoring and management strategies include regular ultrasounds to assess fetal growth, Doppler studies to evaluate blood flow, and possible interventions such as intrauterine transfusions if severe anemia is detected. The management of this condition is crucial to ensure the health of both the mother and the fetus, requiring a multidisciplinary approach involving obstetricians and maternal-fetal medicine specialists.
Detailed documentation of maternal antibody status, fetal monitoring, and any interventions performed.
Management of Rh sensitization, monitoring for fetal anemia, and planning for delivery.
Accurate coding requires understanding of the implications of Rh incompatibility and its management.
Comprehensive records of high-risk assessments, ultrasound findings, and treatment plans.
Complex cases involving fetal growth restriction and intrauterine transfusions.
High-risk pregnancies necessitate thorough documentation to justify interventions and coding.
Used for routine monitoring of fetal growth and well-being in pregnancies complicated by anti-D antibodies.
Document the reason for the ultrasound, including maternal antibody status and any findings.
Obstetricians should ensure that the ultrasound findings are clearly linked to the management of the anti-D antibodies.
Anti-D antibodies can lead to hemolytic disease of the newborn, which may cause severe anemia, jaundice, and other complications in the fetus. Close monitoring and management are essential to mitigate these risks.
